Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 7/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 6/20 | 0.56 |
| ▸ | HPGD | P15428 | 5/20 | 0.56 |
| ▸ | GLA | P06280 | 5/20 | 0.56 |
| ▸ | CASP1 | P29466 | 2/20 | 0.55 |
| ▸ | CASP7 | P55210 | 2/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.55 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3956317 | 0.85 | ALDH1A1 (0.67) | HSD17B3KDM4EALDH1A1HSD17B10LMNA | |
| SCHEMBL12301447 | 0.83 | LMNA (0.51) | HSD17B3KDM4EALDH1A1HSD17B10LMNA | |
| SCHEMBL591899 | 0.80 | HSD17B3 (1.00) | HSD17B3KDM4EALDH1A1HSD17B10LMNA | |
| SCHEMBL31366988 | 0.80 | HSD17B3 (1.00) | HSD17B3KDM4EALDH1A1HSD17B10LMNA | |
| SCHEMBL28446883 | 0.79 | HSD17B3 (0.96) | HSD17B3KDM4EALDH1A1HSD17B10LMNA | |
| SCHEMBL12489574 | 0.78 | ALDH2 (0.48) | HSD17B3KDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL9136261 | 0.77 | ALDH1A1 (0.63) | HSD17B3KDM4EALDH1A1HSD17B10LMNA | |
| SCHEMBL14176730 | 0.77 | KDM4E (0.57) | HSD17B3KDM4EALDH1A1HSD17B10LMNA | |
| SCHEMBL29600967 | 0.77 | KDM4E (1.00) | HSD17B3KDM4EALDH1A1HSD17B10LMNA | |
| SCHEMBL3874542 | 0.77 | KDM4E (1.00) | HSD17B3KDM4EALDH1A1HSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5730962-A | Depigmenting cosmetic or dermatologic composition containing a benzofuran derivative and its use in depigmentating skin | L'OREAL (FR) | 1998-03-24 | — | — | US | claimed |
| EP-0524108-B1 | Use of derivatives of benzofurane as depigmentation agents in cosmetic or dermatological compositions | OREAL (FR) | 1995-06-07 | — | — | EP | claimed |
| WO-2013138744-A1 | COMPOSITIONS FOR THE TREATMENT OF SKIN DISORDERS | M. ALPHABET 1, LLC (US) | 2013-09-19 | — | — | WO | disclosed |
| EP-1277736-B1 | NOVEL BICYCLIC COMPOUNDS | ASAHI KASEI PHARMA CORP (JP) | 2007-08-08 | — | — | EP | disclosed |
| EP-1785421-A1 | TROPAN COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-16 | — | — | EP | disclosed |
| US-7049445-B2 | Bicyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-05-23 | — | — | US | disclosed |
| US-6861444-B2 | Bicyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-03-01 | — | — | US | disclosed |
| US-20040127546-A1 | for treating or preventing diabetes, obesity, hyperlipidemia, digestive diseases, depression or urinary disturbances; beta 3-agonist | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-07-01 | — | — | US | disclosed |
| US-20030191174-A1 | Eating disorders; antidiabetic agents; gastrointestinal disorders | ASAHI KASEI PHARMA CORPORATION (JP) | 2003-10-09 | — | — | US | disclosed |
| CN-1430603-A | Novel bicyclic compounds | ASAHI CHEMICAL IND (JP) | 2003-07-16 | — | — | CN | disclosed |
| EP-1277736-A1 | NOVEL BICYCLIC COMPOUNDS | Asahi Kasei Kabushiki Kaisha (JP) | 2003-01-22 | — | — | EP | disclosed |
| US-5730962-A | Depigmenting cosmetic or dermatologic composition containing a benzofuran derivative and its use in depigmentating skin | L'OREAL (FR) | 1998-03-24 | — | — | US | disclosed |
| EP-0230475-B1 | NOVEL UREA DERIVATIVES, PROCESSES FOR PRODUCTION THEREOF AND HERBICIDE | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1992-03-18 | — | — | EP | disclosed |
| US-4838924-A | NONPHYTOTOXIC | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1989-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127546-A1 | for treating or preventing diabetes, obesity, hyperlipidemia, digestive diseases, depression or urinary disturbances; beta 3-agonist | GPR119, ADRB3, DBH | HSD17B3 45/4885KDM4E 3207/4885ALDH1A1 1438/4885 |
| US-20030191174-A1 | Eating disorders; antidiabetic agents; gastrointestinal disorders | GPR119, GIPR, SLC5A2 | HSD17B3 339/4885KDM4E 1397/4885ALDH1A1 1990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.